Dr James Udelson (Tufts Medical Center, Boston, MA, US) discusses the CAPACITY HFpEF trial which was a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the sGC stimulator praliciguat over 12 weeks in patients with HFpEF.
What does CAPACITY HFpEF aim to address?
Can you tell us about the mechanism of sGC stimulators and why they may help HFpEF patients?
Can you summarise the study design, inclusion criteria and endpoints studied in CAPACITY HFpEF?
What were your findings?
How should this study influence future research in HFpEF?
Recorded remotely from Boston, 2020.
Interviewer: Mirjam Boros
Recording editor: Natascha Wienand